



Synthesis and cytotoxicity evaluation of some new 6-nitro derivatives of thiazole-containing 4-(3H)-quinazolinone

Leila Hosseinzadeh¹, Alireza Aliabadi², Masoud Kalantari³, Abolfazl Mostafavi⁴, and Marzieh Rahmani Khajouei^{2,*}

¹Pharmaceutical sciences Research Center, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, I.R. Iran.

²Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Science, Kermanshah University of Medical Sciences, Kermanshah, I.R. Iran.

³Student Research Committee, School of Pharmacy and Pharmaceutical Science, Kermanshah University of Medical Sciences, Kermanshah, I.R. Iran.

⁴Department of Pharmaceutics and Isfahan Pharmaceutical Sciences Research Center, School of pharmacy and pharmaceutical science, Isfahan University of Medical Sciences, I.R. Iran.

Abstract

Quinazolinones are a group of fused heterocyclic compounds which have valuable biological properties including cytotoxic, antibacterial and antifungal activities. Thiazole group-containing compounds have been also reported to have a wide range of biological activities such as antitumor, anti-inflammatory, analgesic and antibacterial effects. Due to valuable cytotoxic effects of both thiazole groups and quinazolinone derivatives, in this study a series of quinazolinone-thiazole hybrids were synthesized and evaluated for their cytotoxic effects on three cell lines including MCF-7, HT-29, and PC-3. Among tested compounds (quinazolinones and three intermediates), k5 and k6 showed highest cytotoxic activities against PC3 cell line. K6 and C were most active compounds against MCF7 and K6 showed best cytotoxicity on HT-29 cell line.

Keywords: : Quinazolinone; Thiazole; Cytotoxicity

INTRODUCTION

Cancer is a major health problem in developing and undeveloped countries. Although major advances have been made in the treatment of this disease, due to the problems associated with drug resistance, the continued efforts to discover new anticancer agents is very important. To discover various chemical substances which may serve as leads to design new antitumor agents, we are mostly interested in this work with quinazolinone derivatives, which are well known compounds as a new class of anticancer agents with significant therapeutic value against tumors (1). Quinazolinone and their derivatives are building blocks for approximately 150 naturally occurring alkaloids isolated from a number of families of the plant kingdom, from microorganisms and animals (2). There are many reports about biological

activities in synthetic and natural quinazolines including sedative (3), anticonvulsant (3-5), anti-inflammatory (3,6), antitumor (3,7), antibacterial (3,8-10), antifungal (4,5), antitubercular (4,6,8,11), antimalarial (9,12), antiviral (4,6), anti-HIV (3,8-10,13), and hypolipidemic activities (14,15). Some drugs have been synthesized with quinazolinone structure such as cloroqualone (antitussive), diproqualone (analgesic) (16), gefitinib, lapatinib (anticancer) (1), piriqualone (anticonvulsant) (17), doxazocin (antihypertensive) (18), prazosin (antihypertensive) (19), trimetrexate (antibacterial), thymitaq (anticancer) (20) and raltitrexed (anticancer) (21). Thiazole group containing compounds have been also reported to have a wide range of biological activities including: antitumor, anti-inflammatory, analgesic, antibacterial, and antifungal effects (22-25). Thiazole, an important heterocyclic ring, is widely used in

*Corresponding Author: Marzieh Rahmani Khajouei
Tel. 00 31 3137927065, Fax. 00 31 36680011
Email: m_rahmani@pharm.mui.ac.ir

anticancer drug development. Several anticancer agents containing thiazole moiety have been discovered, like bleomycin and tiazofurin. Ritonavir (anti-HIV), meloxicam (anti-inflammatory), nizatidine (anti-peptic ulcer) and penicillin (antibiotic) are some other examples of thiazole bearing products with biological activities (22,26). Due to the valuable cytotoxic effects of both thiazole and quinazolinone compounds, in this study, a series of quinazolinone-thiazole hybrids were synthesized. Furthermore, antiproliferative activity of derivatives was determined using tumor cells in culture against MCF-7, HT-29, and PC-3.

MATERIALS AND METHODS

Instrumentation

All starting materials, reagents and solvents were purchased from commercial suppliers

like Merck (Germany) and Aldrich (USA) companies.

The purity of the prepared compounds was proved by thin layer chromatography (TLC) using various solvents of different polarities. Merck silica gel 60 F254 plates were applied for analytical TLC.

^1H NMR spectra were recorded using a (Bruker 400 MHz, Germany) spectrometer, and chemical shifts are expressed as δ (ppm) with tetramethylsilane (TMS) as internal standard.

The IR spectra were obtained on a Shimadzu 470 spectrophotometer (potassium bromide disks). Melting points were determined using electrothermal melting point analyzer apparatus (IA 9000, UK) and are uncorrected. The mass spectra were run on a Finnigan TSQ-70 spectrometer (Finnigan, USA) at 70 eV. All cell lines were purchased from Pasteur Institute of Iran.




Fig. 1. General reaction for preparation of the final compounds

Preparation of compounds

To produce 6-nitroderivatives of thiazole-containing 4(3H) quinazolinones (K1-K6), the primary amine G was synthesized through a five-step procedure. In the first step, 4-phthalimido-2-butanone (compound B) (Fig. 1), was prepared through the addition of methyl vinyl ketone to phthalimide. In the second step, 1-bromo-4-N-phthalimido-2-butanone (compound C) (Fig. 1) was synthesized by bromination of the methyl group of compound B. Nucleophilic substitution of separately synthesized thiobenzamide (compound E) (Fig. 1) to the brominated intermediate compound C afforded 2-phenyl-4-[(2-N-phthalimido)ethyl]thiazole (compound F) (Fig. 1) which was reacted with hydrazine hydrate and deprotected to produce the 2-phenyl-4-(2-aminoethyl) thiazole (compound G) (Fig. 1). A group of benzoxazinones (J1-J6) with different substituent at position 2 were synthesized. The reaction of the primary amine (compound G) with these benzoxazinones yielded the final compounds as presented in Fig. 1.

Cell culture conditions

PC3 (prostate carcinoma), MCF-7 (breast cancer), and HT-29 (colon carcinoma) cells were maintained at 37 °C in a humidified atmosphere (90%) containing 5% CO₂. PC3, MCF-7, and HT-29 cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) with 5% v/v fetal bovine serum, 100 U/ml penicillin, and 100 mg/mL streptomycin. The medium was changed every two to three days and sub-cultured when the cell population density reached to 70–80% confluence. Cells were seeded at an appropriate density according to each experimental design (27).

Cytotoxicity assay

HT-29, MCF-7, and PC-3 cells were seeded in triplicate on 96-well tissue culture plates (15 × 10³ cells/well) and incubated overnight. Cells were treated with different concentrations of the derivatives (0-275 μM) for 24 h. Then the medium was removed and the MTT substrate was prepared in a physiologically balanced solution (PBS), added to cells in culture, at a final

concentration of 0.5 mg/ml, and incubated for 1 to 4 h. The formazan crystals were solubilized in dimethyl sulfoxide (DMSO) and the quantity of formazan (presumably directly proportional to the number of viable cells) was measured by recording changes in absorbance at 570 nm using a plate reading spectrophotometer. Cell viability was calculated using following formula:

$$\% \text{ Cell Survival} = \frac{\text{Mean absorbance in drug treated wells} - \text{Mean absorbance in blank}}{\text{Mean absorbance in control wells} - \text{Mean absorbance in blank}} \times 100$$

IC₅₀ values were calculated by plotting the cell viability against compound concentrations (27).

RESULTS

Details of preparation procedures and chemistry of synthesized compounds

4-Phthalimido-2-butanone (B)

To a well-stirred suspension of phthalimide (compound A) (Fig. 1) (36.75 g, 250 mmol) and 3-buten-2-one (17.5 g, 250 mmol) in 250 ml of ethyl acetate (EtOAc) was added a freshly prepared solution of sodium ethoxide (NaOEt) (0.67 g, 12 mmol) in 65 ml of anhydrous ethanol (EtOH) under an N₂ atmosphere. After 2 h stirring at ambient temperature, the mixture was refluxed until an almost clear solution was obtained and refluxing was continued for an additional 2 h. After cooling, the solvent was removed *in vacuo* and the solid residue was crystallized from hot 96% EtOH to obtain compound B as a white powder (28). Yield: 92%, m.p 112°C, (Found: M217, C₁₂H₁₁NO₃ requires 217), $\nu_{\text{max}} = 3010, 2925, 1700 \text{ cm}^{-1}$, ¹HNMR (400 MHz, CDCl₃) δ : 2.16 (3H, s, H-C^h), 2.85 (2H, t, *J* = 7.2 Hz, H-C^g), 3.93 (2H, t, *J* = 7.2 Hz, H-C^f), 7.65-7.75 (2H, m, H-C^b Ar), 7.77-7.85 (2H, m, H-C^a Ar).

1-bromo-4-N-phthalimido-2-butanone (C)

4-Phthalimido-2-butanone (compound B) (14 g, 64 mmol) was dissolved in methylene chloride (105 ml) and methanol (85 ml). A solution of bromine (3.3 ml, 64 mmol) in methanol (20 ml) was added dropwise over a 2 h period. The reaction mixture was allowed

to stir overnight, and was then treated with additional bromine (0.8 ml, 15.6 mmol); after 1 h, no starting material was visible by TLC (10:1, chloroform:EtOAc). The reaction mixture was concentrated *in vacuo* to leave a yellow solid, which was triturated with diethyl ether and dried with nitrogen flow to give compound C as white solid (29). Yield: 65%, m.p 105 °C, (Found: M296, C₁₂H₁₀BrNO₃ requires 296), ν_{\max} = 3001, 2920, 1708 cm⁻¹, ¹HNMR (400 MHz, CDCl₃) δ : 3.11 (2H, t, *J* = 7.2 Hz, H-C^g), 3.92 (2H, s, H-C^h), 4.0 (2H, t, *J* = 7.2 Hz, H-C^f), 7.70-7.77 (2H, m, H-C^b Ar), 7.80-7.90 (2H, m, H-C^a Ar).

Thiobenzamide (E)

To a solution of 7.9 g (99 mmol) of 70% sodium hydrosulfide hydrate and 10.1 g (50 mmol) of magnesium chloride hexahydrate in 100 ml of dimethylformamide (DMF) was added 5.15 g (50 mmol) of benzonitrile (compound D) (Fig. 1) in one portion, and the mixture was stirred at room temperature for 90 min. The resulting green solution was poured into 200 ml of water, and the product was extracted with diethyl ether. After evaporation of ether *in vacuo*, the crude product was suspended in 1N HCl and stirred for 20 min, then filtered and washed with water to give compound E (30). Yield: 82%, m.p. 187 °C, (Found: M137, C₇H₇NS requires 137), ν_{\max} = 3356, 3155, 1624 cm⁻¹, ¹HNMR (400 MHz, CDCl₃) δ : 7.34 (2H, t, *J* = 7.6 Hz, H-C², H-C⁴ Ar), 7.45 (1H, t, *J* = 7.6 Hz, H-C³ Ar), 7.8 (2H, d, *J* = 7.6 Hz, H-C¹, H-C⁵ Ar).

2- phenyl - 4 - [(2 - N - phthalimido) ethyl] thiazole (F)

1-Bromo-4-phthalimido-2-butanone (compound C) (5.92 g, 20 mmol) and thiobenzamide (compound E) (5.48 g, 40 mmol), were mixed with *n*-propanol (100 ml) and concentrated hydrochloric acid (10 ml) and the reaction mixture was heated to reflux for 2 h. After cooling, the precipitate was filtered and washed with *n*-propanol and then by diethyl ether. The hydrochloride product was obtained as a white solid. The free base, was obtained as follow: the product was mixed with saturated aqueous potassium carbonate solution overnight at room temperature. The

solid was filtered, washed with water, diethyl ether and air-dried to leave compound F as a white solid (31). Yield: 55%, m.p 120 °C, (Found: M334, C₁₉H₁₄N₂O₂S requires 334), ν_{\max} = 3116, 2947, 1705 cm⁻¹, ¹HNMR (400 MHz, CDCl₃) δ : 3.23 (2H, t, *J* = 6.6 Hz, H-C^g), 4.11 (2H, t, *J* = 6.6 Hz, H-C^f), 6.99 (1H, s, H-C^c), 7.32-7.38 (3H, m, H-C^bAr), 7.68-7.72 (2H, m, H-C^dAr), 7.76-7.80 (2H, m, H-C^eAr), 7.81-7.85 (2H, m, H-C^aAr).

2-phenyl-4-(2-aminoethyl) thiazole (G)

Compound F (3.67 g, 11 mmol) was added to a solution of hydrazine in methanol (200 ml, 4.0 M), and the reaction mixture was heated for 0.5 h until it became homogenous. The reaction mixture was then stirred at room temperature for further 2 h. Concentration *in vacuo* provided a white solid, which was purified by column chromatography (eluent: 89:10:1 chloroform:methanol: concentrated ammonium hydrochloride). The title product was obtained as sticky oil (31). Yield: 32%, (Found: M204, C₁₁H₁₂N₂S requires 204), ν_{\max} = 3368, 1654 cm⁻¹, ¹HNMR (400 MHz, CDCl₃) δ : 1.6-1.8 (2H, bs, NH₂), 2.93 (2H, t, *J* = 6.0 Hz, H-C^d), 3.07-3.17 (2H, m, H-C^e), 6.93 (1H, m, H-C^c), 7.36-7.45 (3H, m, H-C^b), 7.88-7.96 (2H, m, H-C^a).

N-Acyl 5-nitroanthranilic acid (I)

Acyl chloride (0.37 mol) was added dropwise to a mixture of 5-nitroanthranilic acid (compound H) (0.25 mol) (Fig. 1) in dimethyl formamide (125 ml) at such rate that the temperature of the mixture did not rise above 40 °C. The mixture was stirred at room temperature for at least an additional 3 h. Completion of the reaction was determined by TLC and the mixture was poured into water (1 L) and stirred for 1 h. The precipitated product was collected by filtration, washed with cold water and dried under reduced pressure yielding (compound I) (Fig. 1) as a white powder. Yield: 55-70%.

2- substituted - 6 - nitro - 1,3 - benzoxazin - 4 - one (J1-J6)

Compound I (0.125mol) was dissolved in acetic anhydride (90 ml) and slowly heated to 170-180 °C in a round-bottom flask equipped

with a magnetic stirrer bar and a claisen-distillation head. Completion of the reaction was confirmed by TLC (20:1, chloroform:methanol), and the produced acetic acid was distilled under reduced pressure. The residue was then cooled and product was washed by n-hexane to give 3(2-methyl-6-nitro-1,3-benzoxazin-4-one) (compound J) (Fig. 1) as yellow crystals (32). Yield: 65-84%.

6-Nitroderivatives of thiazole containing 4(3H) quinazolinones (K1-K6)

To prepare 2-substituted-6-nitro-3-(2-(2-phenylthiazole-4-yl) ethyl) quinazolin-4(3H)-ones, 0.5 mmol of related benzoxazine was refluxed with 1 mmol of amine (compound G) in chloroform (10 ml) for 6-7 h. After completion of the reaction, chloroform was evaporated under reduced pressure and the residue was treated with ethylene glycol (5 ml) and NaOH pellets (0.003 g) in a flask equipped with a claisen-distillation head. The mixture was reheated to 130-140 °C for 5 h. After completion of the reaction, the clear solution was allowed to cool to room temperature and kept overnight to precipitate which was then crystallized from 2-propanol to obtain final products.

2 - ethyl - 6 - nitro - 3 - (2 - (2 - phenylthiazol - 4-yl)ethyl)quinazolin-4(3H)-one (K1)

Yield: 45%, m.p 203 °C, (Found : M406, C₂₁H₁₈N₄O₃S requires 406), ν_{\max} = 2997, 2912, 1658, 1535, 1311 cm⁻¹, ¹HNMR (400 MHz, CDCl₃) δ : 1.28 (3H, t, *J* = 8.0Hz, CH₃:R), 2.77 (2H, q, *J* = 8.0 Hz, CH₂:R), 3.22(2H, t, *J* = 8.0 Hz, H-C₁₀), 4.74(2H, t, *J* = 8.0 Hz, H-C₉), 6.89 (1H,s, H-C₁₂), 7.28-7.40 (3H, m, H-C₁₇, H-C₁₈, H-C₁₉), 7.67 (1H, d, *J* = 8.0 Hz, H-C₈), 7.75-7.83 (2H,m, H-C₁₆, H-C₂₀), 8.43 (1H, dd, *J* = 6.4, *J* = 2.8, H-C₇), 9.07 (1H, d, *J* = 2.8Hz, H-C₅)

6 - nitro - 2 - (4 - nitrophenyl) - 3 - (2 - (2 - phenylthiazol-4-yl)ethyl)quinazolin-4(3H)-one (K2)

Yield: 54%, m.p 218 °C (Found: M499, C₂₅H₁₇N₅O₅S requires 499), ν_{\max} = 3105, 2850, 1678, 1516, 1334 cm⁻¹, ¹HNMR (400 MHz, CDCl₃) δ : 3.23 (2H, t, *J* = 6.4 Hz, H-C₁₀), 4.47 (2H, t, *J* = 6.8Hz, H-C₉), 6.88 (1H, s, H-C₁₂), 7.30-7.50(5H, m, H-C₁₇, H-C₁₈, H-C₁₉, Ph-2H:R), 7.60-7.90 (5H, m, H-C₁₆, H-C₂₀, H-

C₈, Ph-2H:R), 8.42 (1H, dd, *J* = 6.4Hz, *J* = 2.8Hz, H-C₇), 9.06(1H, d, *J* = 2.4 Hz, H-C₅)

2 - methyl - 6 - nitro-3 - (2 - (2 - phenylthiazol-4-yl)ethyl)quinazolin-4(3H)-one (K3)

Yield: 52%, m.p 197 °C, (Found: M392, C₂₀H₁₆N₄O₃S requires 392), ν_{\max} = 3101, 2924, 1678, 1516, 1334 cm⁻¹, ¹HNMR (400 MHz, CDCl₃) δ : 2.51 (3H, s, CH₃:R), 3.23 (2H, t, *J* = 8.0 Hz, H -C₁₀), 4.46 (2H, t, *J* = 8.0 Hz, H-C₉), 6.88 (1H, s, H-C₁₂), 7.30-7.42 (3H, m, H-C₁₇, H-C₁₈, H-C₁₉), 7.62 (1H, d, *J* = 8.0 Hz, H-C₈), 7.73-7.87 (2H, m, H-C₁₆, H-C₂₀), 8.42 (1H, dd, *J* = 8.0 Hz, *J* = 2.8 Hz, H-C₇), 9.06 (1H, d, *J* = 2.4 Hz, H-C₅)

6-nitro-3-(2-(2-phenylthiazole-4-yl)ethyl)-2-propylquinazolin-4(3H)-one (K4)

Yield: 75%, m.p 215 °C, (Found: M420, C₂₂H₂₀N₄O₃S requires 420), ν_{\max} = 3101, 2870, 1689, 1512, 1330 cm⁻¹, ¹HNMR (400 MHz, CDCl₃) δ : 0.95 (3H, t, *J* = 8.0 Hz, CH₃:R), 1.74 (2H, hex, *J* = 8.0 Hz, CH₂:R), 2.68 (2H, t, *J* = 8.0Hz, CH₂:R), 3.22 (2H, t, *J* = 8.0 Hz, H-C₁₀), 4.74 (2H, t, *J* = 8.0 Hz, H-C₉), 6.88 (1H, s, H-C₁₂), 7.30-7.39 (3H, m, H-C₁₇, H-C₁₈, H-C₁₉), 7.64 (1H, d, *J* = 8.0Hz, H-C₈), 7.75-7.85 (2H, m, H-C₁₆, H-C₂₀), 8.42 (1H, dd, *J* = 8.0, *J* = 2.4, H-C₇), 9.06 (1H, d, *J* = 2.4Hz, H-C₅)

6 - nitro - 2 - phenyl - 3 - (2-(2-phenylthiazole-4-yl)ethyl)quinazolin-4(3H)-one (K5)

Yield: 49%, m.p 187 °C, (Found: M454, C₂₅H₁₈N₄O₃S requires 454), ν_{\max} = 3101, 1689, 1504, 1315 cm⁻¹, ¹HNMR (400 MHz, CDCl₃) δ : 3.26 (2H, t, *J* = 6.0 Hz, H-C₁₀), 4.44 (2H, t, *J* = 6.0Hz, H-C₉), 6.84 (1H, s, H-C₁₂), 7.30-7.45 (4H, m, H-C₁₇, H-C₁₈, H-C₁₉, Ph-1H:R), 7.60-8.05 (7H, m, H-C₁₆, H-C₂₀, H-C₈, Ph-4H:R), 8.43 (1H, dd, *J* = 6.4Hz, *J* = 2.8Hz, H-C₇), 9.11(1H, d, *J* = 2.4 Hz, H-C₅)

2 - (4 - chlorophenyl) - 6 - nitro - 3 - (2 - (2 - phenylthiazole-4-yl)ethyl)quinazolin-4(3H)-one (K6)

Yield: 61%, m.p 210 °C, (Found: M488, C₂₅H₁₇ClN₄O₃S requires 488), ν_{\max} = 3101, 2927, 1681, 1516, 1338 cm⁻¹, ¹HNMR (400 MHz, CDCl₃) δ : 3.03 (2H, t, *J* = 6.4 Hz, H-C₁₀), 4.44 (2H, t, *J* = 6.8Hz, H-C₉), 6.96 (1H, s, H-C₁₂), 7.30 (2H, d, *J* = 8.4 Hz, H-C₁₆, H-

C₂₀), 7.32-7.37 (4H, m, H-C₁₇, H-C₁₉, Ph-2H:R), 7.38-7.40 (2H, m, H-C₁₈, H-C₈), 7.70 (1H, dd, $J = 6.4\text{Hz}$, $J = 2.8\text{ Hz}$, H-C₇), 7.84-7.87 (2H, m, Ph-2H:R), 9.06 (1H, d, $J = 2.4\text{ Hz}$, H-C₅).

Antiproliferative effects of the derivatives

MTT assay results for evaluation of cytotoxic effects of the compounds are shown in Figs. 2, 3, and 4. Their IC₅₀ (μM) values are also listed in Table 1.




Fig. 2. The percentage of cytotoxicity versus concentration by MTT exclusion on MCF-7 cancer cell line. IC₅₀ value was obtained by plotting the percentage of proliferation values versus drug concentrations. Data are expressed as the mean ± SEM of three separate experiments.




Fig. 3. The percentage of cytotoxicity versus concentration by MTT exclusion on HT-29 cancer cell line. IC₅₀ value was obtained by plotting the percentage of proliferation values versus drug concentrations. Data are expressed as the mean ± SEM of three separate experiments.




Fig. 4. The percentage of cytotoxicity versus concentration by MTT exclusion on PC-3 cancer cell line. IC₅₀ value was obtained by plotting the percentage of proliferation values versus drug concentrations. Data are expressed as the mean ± SEM of three separate experiments.

Table 1. The IC₅₀ (μM) of tested compounds against MCF-7, HT-29, and PC-3 cancer cell lines

Cell Line Compound	R	MCF7	HT-29	PC3
K1	-CH ₃ -CH ₂ -	80 ± 3.5	> 250	> 250
K2	-C ₆ H ₄ NO ₂	> 250	> 250	> 250
K3	CH ₃	108 ± 2.1	> 250	> 250
K4	-CH ₂ -CH ₂ - CH ₃	32 ± 0.56	90 ± 6.37	42 ± 3.56
K5	-C ₆ H ₅	32 ± 3.25	37 ± 4.98	23 ± 1.94
K6	-C ₆ H ₄ Cl	17 ± 0.367	24 ± 1.56	23 ± 1.02
Compound C	-	17 ± 2.068	25 ± 2.58	28 ± 0.063
Compound F	-	31 ± 0.751	40 ± 6.1	> 250
Compound G	-	28 ± 0.823	26 ± 3.401	32 ± 0.905




Fig. 5. Amine generation mechanism.

DISCUSSION

The synthesized 4(3H) quinazolinones in this study contained 4-ethyl-2-phenylthiazole group on position 3 of quinazolinone structure. For preparation of these quinazolinones, a primary amine containing thiazole (compound G) (Fig. 1) was synthesized. The most practical method to prepare thiazoles is Hantzsch reaction which involves the condensation of α -haloketones and thiourea or thioamides in refluxing alcohol. Phthalimide as an NH_2 -synthon was used here for the preparation of the amine. Application of phthalimide in Gabriel synthesis for preparation of primary amines is well documented. After alkylation, the resulting alkyl phthalimide is reacted with hydrazine. The desired primary amine could be generated by reacting with hydrazine hydrate. Consequently phthalazine as a stable cyclic product is formed and precipitated (Fig. 5). The reaction of 2-phenyl-4-(2-aminoethyl)thiazole (compound G) with different benzoxazinones resulted in the production of new 4(3H)quinazolinones (Fig. 1).

CONCLUSION

In this study, quinazolinones as biologically active compounds were conjugated with another well-known moiety (thiazole ring) in a multi-step reaction procedure to produce interesting novel compounds. All synthesized compounds were tested for their cytotoxic effects on three cell lines including MCF-7,

HT-29, and PC-3 of which quinazolinones K1-K6 and three intermediates, compound C, F, and G, k5 and k6 showed highest cytotoxic activities against PC3 cell line. K6 and compound C were most active against MCF-7 and K6 showed best cytotoxicity on HT-29 cell line.

ACKNOWLEDGEMENT

Authors appreciate Research Council of Kermanshah University of Medical Sciences for financial support of this project.

REFERENCES

1. El-Azab A, Al-Omar M, Abdel-Aziz A, Abdel-Aziz N, El-Sayed M, Aleisa A, *et al.* Design, synthesis and biological evaluation of novel quinazolinone derivatives as potential antitumor agents: Molecular docking study. *Eur J Med Chem.* 2010;45:4188-4198.
2. Tiwari A, Singh V, Bajpai A, Shukla G, Singh S, Mishra A. Synthesis and biological properties of 4-(3H)-quinazolinone derivatives. *Eur J Med Chem.* 2007;42:1234-1238.
3. Mhaske SB, Argade NP. The chemistry of recently isolated naturally occurring quinazolinone alkaloids. *Tetrahedron.* 2006;62:9787-9826.
4. Gursoy A, Unal B, Karali N, Otuk G. Synthesis, Characterization and Primary Antimicrobial Activity Evaluation of 3-Phenyl-6-methyl-4-(3H)-quinazolinone-2-yl-mercaptoacetic Acid Arylidenehydrazides. *Turk J Chem.* 2005;29:233-245.
5. Mourad AE, Aly AA, Farag HH, Beshr EA. Microwave assisted synthesis of triazoloquinazolinones and benzimidazoquinazolinones. *Beilstein J Org Chem.* 2007;3:1-5.
6. Zhou Y, Murphy DE, Sun Z, Gregor VE. Novel parallel synthesis of N-(4-oxo-2-substituted-4-H-

- quinazolin-3-yl)-substituted sulfonamides. *Tetrahedron Lett.* 2004;45:8049-8051.
7. Dinakaran M, Selvam P, DeClercq E, Sridhar SK. Synthesis, antiviral and cytotoxic activity of 6-bromo-2, 3-disubstituted-4 (3H)-quinazolinones. *Biol & Pharm Bull.* 2003;26:1278-1282.
 8. Raghavendra NM, Thampi P, Gurubasavarajaswamy PM, Sriram D. Synthesis and antimicrobial activities of some novel substituted 2-Imidazolyl-N-(4-oxoquinazolin-3 (4H)-yl)-acetamides. *Chem Pharm Bull.* 2007;55:1615-1619.
 9. Laddha SS, Wadodkar SG, Meghal SK. Studies on some biologically active substituted 4(3H)-quinazolinones. Part 1: Synthesis, characterization and anti-inflammatory-antimicrobial activity of 6, 8-disubstituted 2-phenyl-3-[substituted-benzothiazol-2-yl]-4 (3H)-quinazolinones. *Arkivoc.* 2006;11:1-20.
 10. Pandeya SN, Sriram D, Nath G, De Clercq E. Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin derivatives with 3-amino-2-methylmercaptoquinazolin-4 (3H)-one. *Pharm Acta Helvet.* 1999;74:11-17.
 11. Nanda AK, Ganguli S, Chakraborty R. Antibacterial activity of some 3-(Arylideneamino)-2-phenylquinazolinone-4(3H)-ones: synthesis and preliminary QSAR studies. *Molecules.* 2007;12:2413-2426.
 12. Philipova I, Dobrikov G, Krumova K, Kaneti J. Convenient synthesis of some 2 substituted 4 (3H) quinazolinone derivatives. *J Heterocycl Chem.* 2006;43:1057-1063.
 13. Gürsoy A, Karali N. Synthesis and primary cytotoxicity evaluation of 3-[[[3-phenyl-4 (3H)-quinazolinone-2-yl] mercaptoacetyl] hydrazono]-1H-2-indolinones. *Eur J Med Chem.* 2003;38:633-643.
 14. Ghabrial SS, Gaber HM. Dipolar cycloaddition reactions with quinazolinones: a new route for the synthesis of several annelated pyrrolo and pyridazinoquinazolinone derivatives. *Molecules.* 2003;8:401-410.
 15. Refaie FM, Esmat AY, Gawad SMA, Ibrahim AM, Mohamed MA. The antihyperlipidemic activities of 4 (3H) quinazolinone and two halogenated derivatives in rats. *Lipids Health Dis.* 2005;4:22-33.
 16. Shcherbakova I, Balandrin MF, Fox J, Ghatak A, Heaton WL, Conklin RL. 3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis. *Bioorg Med Chem Lett.* 2005;15:1557-1560.
 17. Liu JF, Lee J, Dalton AM, Bi G, Yu L, Baldino CM, *et al.* Microwave-assisted one-pot synthesis of 2, 3-disubstituted 3H-quinazolin-4-ones. *Tetrahedron Lett.* 2005;46:1241-1244.
 18. Piller LB, Davis B, Cutler JA, Cushman WC, Wright JT, Williamson JD, *et al.* Validation of heart failure events in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) participants assigned to doxazosin and chlorthalidone. *Curr Contr Trials Cardio Med.* 2002;3:1-10.
 19. Akazome M, Yamamoto J, Kondo T, Watanabe Y. Palladium complex-catalyzed intermolecular reductive N-heterocyclization: novel synthesis of quinazolinone derivatives from 2-nitrobenzaldehyde or 2-nitrophenyl ketones with formamide. *J Organomet Chem.* 1995;494:229-233.
 20. Al-Omary FAM, Abou-zeid LA, Nagi MN, Habib ESE, Abdel-Aziz AAM, El-Azab AS, *et al.* Non-classical antifolates. Part 2: Synthesis, biological evaluation, and molecular modeling study of some new 2, 6-substituted-quinazolin-4-ones. *Bioorg Med Chem.* 2010;18:2849-2863.
 21. Cao SL, Feng YP, Jiang YY, Liu SY, Ding GY, Li RT. Synthesis and in vitro antitumor activity of 4(3H)-quinazolinone derivatives with dithiocarbamate side chains. *Bioorg Med Chem Lett.* 2005;15:1915-1917.
 22. Bharti S, Nath G, Tilak R, Singh S. Synthesis, antibacterial and anti-fungal activities of some novel Schiff bases containing 2, 4-disubstituted thiazole ring. *Eur J Med Chem.* 2010;45:651-660.
 23. Khalil A, Berghot M, Gouda M. Synthesis and antibacterial activity of some new thiazole and thiophene derivatives. *Eur J Med Chem.* 2009;44:4434-4440.
 24. Pandeya S, Sriram D, Nath G, DeClercq E. Synthesis, antibacterial, antifungal and anti-HIV activities of schiff and mannich bases derived from isatin derivatives and N-[4-(4'-chlorophenyl) thiazol-2-yl] thiosemicarbazide. *Eur J Pharm Sci.* 1999;9:25-31.
 25. Cukurovali A, Yilmaz I, Gur S, Kazaz C. Synthesis, antibacterial and antifungal activity of some new thiazolylhydrazone derivatives containing 3-substituted cyclobutane ring. *Eur J Med Chem.* 2006;41:201-207.
 26. Li J, Xu Z, Tan M, Su W, Gong X. 3-(4-(Benzo[d]thiazol-2-yl)-1-phenyl-1H-pyrazol-3-yl) phenyl acetate induced Hep G2 cell apoptosis through a ROS-mediated pathway. *Chemico Biol Interact.* 2010;183:341-348.
 27. Luo Y, Xiao F, Qian S, Lu W, Yang B. Synthesis and in vitro cytotoxic evaluation of some thiazolylbenzimidazole derivatives. *Eur J Med Chem.* 2011;46:417-422.
 28. Eriks JC, Van der Goot H, Sterk GJ, Timmerman H. Histamine H2-receptor agonists. Synthesis, in vitro pharmacology, and qualitative structure-activity relationships of substituted 4-and 5-(2-aminoethyl) thiazoles. *J Med Chem.* 1992;35:3239-3246.
 29. Brighty KE, Lowe JA, Mcguirk PR. Heterocyclic-substituted quinoline-carboxylic acids. US patent 5037834. 1991.
 30. Manaka A, Sato M. Synthesis of Aromatic Thioamide from Nitrile Without Handling of Gaseous Hydrogen Sulfide. *Chem Inform.* 2005;36:761-764.
 31. Walczyski K, Timmerman H, Zuiderveld O, Zhang M, Glinka R. Histamine H1 receptor ligands: Part I. Novel thiazol-4-ylethanamine derivatives: synthesis

- and in vitro pharmacology. *Il Farmaco*. 1999;54:533-541.
32. Al-Obaid AM, Abdel-Hamide SG, El-Kashef HA, Abdel-Aziz AA, El-Azab AS, Al-khamees HA, *et al.* Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4(3H)-quinazolinone analogs. *Eur J Med Chem*. 2009; 44: 2379–91.